Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cooper-Standard

26.34
+2.249.29%
Post-market: 28.502.16+8.20%19:50 EDT
Volume:947.01K
Turnover:27.04M
Market Cap:462.22M
PE:-10.20
High:30.82
Open:28.57
Low:26.15
Close:24.10
Loading ...

Man accused of lacing sweets as kids fall ill at UK camp

CNA
·
9 hours ago

Cooper-Standard Reports Strong Q2 2025 Performance

TIPRANKS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-CNH Industrial, Newmont, Dominion Energy

Reuters
·
01 Aug

CPS Technologies Reports Record Q2 2025 Revenue

TIPRANKS
·
01 Aug

Cooper-Standard Shares Surge to New 52-Week High After Boosted Guidance, Narrowed 2Q Loss

Dow Jones
·
01 Aug

Cooper-Standard Reports Q2 2025: Sales at $706M, Net Loss Improves by $74.8M, Adjusted EPS Rises to $0.06

Reuters
·
01 Aug

Cooper-Standard Holdings Q2 Adj. EPS $0.06 Beats $(0.06) Estimate, Sales $705.97M Beat $687.00M Estimate

Benzinga
·
01 Aug

Cooper-Standard Holdings Inc Outlook FY Sales $2.7 Bln - $2.8 Bln

THOMSON REUTERS
·
01 Aug

Cooper Standard Q2 Gross Profit USD 93.051 Million

THOMSON REUTERS
·
01 Aug

Cooper-Standard Holdings Inc: Overall Light Vehicle Production Volumes May Be Impacted by Changing Trade Policies

THOMSON REUTERS
·
01 Aug

Cooper Standard Raises Full Year Adjusted Ebitda Guidance as Second Quarter and First Half Results Exceed Expectations

THOMSON REUTERS
·
01 Aug

CPS Technologies Q2 EPS $0.01 Up From $(0.07) YoY, Sales $8.079M Up From $5.030M YoY

Benzinga
·
31 Jul

Cooper-Standard Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
30 Jul

Cooper Standard to Present at J.P. Morgan Auto Conference in New York City

Reuters
·
29 Jul

Cooper-Standard Holdings' (NYSE:CPS) Returns On Capital Are Heading Higher

Simply Wall St.
·
29 Jul

CPS Announces $418.33 Million Senior Subordinate Asset-Backed Securitization

GlobeNewswire
·
29 Jul

CPS Technologies Corp. Conference Call Notification

GlobeNewswire
·
28 Jul

Great British Railways risk repeating British Rail mistakes

cityam
·
28 Jul

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

GlobeNewswire
·
18 Jul

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

GlobeNewswire
·
16 Jul